ArticleProbiotics and antimicrobial proteins2026
Amelioration of Listeria monocytogenes infection in mice by live and pasteurized Faecalibacterium prausnitzii and its cell-free supernatant and its association with strengthened gut barrier and downregulated TLR4/NF-κB pathway.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Listeria monocytogenes is a common foodborne pathogen that poses a serious health risk. Faecalibacterium prausnitzii is one of the major members of the gut microbiota and is considered essential for maintaining gut health. The aim of this study was to investigate the effect of live F. prausnitzii (FP), pasteurized F. prausnitzii (pFP) and its cell-free supernatant (CFS) on the susceptibility of mice to L. monocytogenes infection and to explore the underlying mechanisms. Safety evaluation results indicated that FP, pFP, and CFS showed no toxic effects in healthy mice. In L. monocytogenes-infected mice, these treatments significantly decreased bacterial counts in various organs and feces, and alleviated inflammation. Furthermore, the interventions significantly upregulated short-chain fatty acid (SCFA) levels, particularly acetate and propionate, and modulated the gut microbiota composition after infection. In addition, RT-qPCR and western blot results showed that they reduced inflammatory factors and intestinal damage, which is associated with downregulation of the TLR4/NF-κB pathway. Taken together, these results suggest that FP, pFP and CFS attenuate L. monocytogenes infection in mice and could be potentially developed as an alternate strategy for prevention or mitigation of L. monocytogenes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.